Epigenetics is the next frontier of genome science. Put simply: a change of phenotype without change in genotype; look at it more closely, and it opens a myriad of new avenues for research from evolutionary biology through physiology to pharmacology. But how far have we gone in our understanding of basic epigenetic processes and is epigenetics ready yet to revolutionise medicine?
On November 24th, the Innovation Forum will present "Epigenetic Innovation in Pharmacology", an event exploring the newest findings in the field of epigenetics, their potential, and the road to their successful application
An evening event including talks, a panel discussion, startup pitches, and a networking session.
Dr Leila Luheshi, Head of Science, PHG Foundation
- Leila Luheshi is the Head of Science at the PHG Foundation, where she is responsible for the delivery of the scientific expertise and analysis that underpin their work. She is a Junior Associate Fellow at the Cambridge Centre for Science and Policy (CSaP) and has previously worked in the Research Base of the Department for Business, Innovation and Skills where she shaped the government's industrial strategy.
Dr Nessa Carey, International Director at PraxisUnico
- Nessa Carey is a Visiting Professor at Imperial College and worked in epigenetic drug discovery for 10 years in biotech companies and at Pfizer. She is the editor of the 2015 volume 'Epigenetics and Drug Discovery' from the Royal Society of Chemistry and the author of the popular science books 'The Epigenetics Revolution and Junk DNA: A Journey Through The Dark Matter of the Genome'.
Professor Wolf Reik, Associate Director of the Babraham Institute, University of Cambridge
- Wolf Reik is the Head of the Epigenetics Programme at the Babraham Institute in Cambridge and its Associate Director. He is honorary Professor of Epigenetics at the University of Cambridge and Associate Faculty at the Wellcome Trust Sanger Institute, where he is a founding member of the recently established Centre for Single Cell Genomics. He is a Member of EMBO, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society, Member of the Academia Europaea, and a Thompson Reuter highly cited researcher. His research interests are in epigenetics, particularly in epigenetic reprogramming during mammalian development and its role in stem cell biology and inheritance.